Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)

Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.

Inclusion Criteria:Patients (male or female) less than 50 y.o with :Splanchnic venous territory thrombosis orCerebral venous thrombosis orVenous thrombosis of the upper limb orPulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or1 episode of deep vein thrombosis + 1 episode of arterial thrombosisExclusion Criteria:Presence of a major or minor transient venous thrombosis risk factor:Surgery within the last 3 months preceding the qualifying thrombotic episodeLower limb fracture with immobilization > 3 days in the last 3 months preceding the qualifying thrombotic episodePresence of estro-progestational contraceptionPregnancyImmobilization for acute medical reasons within the last 3 months preceding the qualifying thrombotic episodeAir or car travel > 6 hoursPresence of a major or minor persistent risk factor for venous thrombosis:Presence of active cancer (solid cancer or hematologic malignancy)Chronic inflammatory digestive or joint diseasesOngoing treatment with heparin (low molecular weight heparin (LMWH) or unfractionated heparin (UFH))Presence of an abnormality on the thrombophilia test among the following abnormalitiesProtein C deficiencyProtein S deficiencyAnti-thrombin deficiencyHeterozygous or homozygous factor II mutationHeterozygous or homozygous factor V mutationPresence of anti-phospholipid syndromePresence of myeloproliferative neoplasiaPresence of paroxysmal nocturnal hemoglobinuria